These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29425664)

  • 1. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
    Grabner M; Hepp Z; Raval A; Tian F; Khera M
    J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics, Health Care Utilization and Costs Among Men with Primary or Secondary Hypogonadism in a US Commercially Insured Population.
    Grabner M; Bodhani A; Khandelwal N; Palli S; Bonine N; Khera M
    J Sex Med; 2017 Jan; 14(1):88-97. PubMed ID: 27939338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
    Chen T; Li S; Eisenberg ML
    J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis.
    Schoenfeld MJ; Shortridge E; Cui Z; Muram D
    J Sex Med; 2013 May; 10(5):1401-9. PubMed ID: 23464534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
    Rhoden EL; Morgentaler A
    J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
    Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
    J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
    Khera M; Miner M; Jaffe J; Pastuszak AW
    J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Morbidity and Mortality in Men - Findings From a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone.
    Fallara G; Pozzi E; Belladelli F; Corsini C; Boeri L; Capogrosso P; Montorsi F; Salonia A
    J Sex Med; 2022 Aug; 19(8):1243-1254. PubMed ID: 35753891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The direct and indirect costs among U.S. privately insured employees with hypogonadism.
    Kaltenboeck A; Foster S; Ivanova J; Diener M; Bergman R; Birnbaum H; Kinchen K; Swindle R
    J Sex Med; 2012 Sep; 9(9):2438-47. PubMed ID: 22738380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies.
    Corona G; Rastrelli G; Di Pasquale G; Sforza A; Mannucci E; Maggi M
    J Sex Med; 2018 Jun; 15(6):820-838. PubMed ID: 29803351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Male Hypogonadism With Risk of Hospitalization for COVID-19.
    Dhindsa S; Champion C; Deol E; Lui M; Campbell R; Newman J; Yeggalam A; Nadella S; Ahir V; Shrestha E; Kannampallil T; Diwan A
    JAMA Netw Open; 2022 Sep; 5(9):e2229747. PubMed ID: 36053534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated With Topical Testosterone.
    Muram D; Kaltenboeck A; Boytsov N; Hayes-Larson E; Ivanova J; Birnbaum HG; Swindle R
    Am J Mens Health; 2015 Nov; 9(6):496-505. PubMed ID: 25271142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data.
    Alwani M; Yassin A; Talib R; Al-Qudimat A; Aboumarzouk O; Al-Zoubi RM; Saad F; Haider KS; Al Ansari A
    Vasc Health Risk Manag; 2021; 17():497-508. PubMed ID: 34465997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
    Lundy SD; Parekh NV; Shoskes DA
    J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic benefits with adherence to testosterone therapy in men with hypogonadism and type 2 diabetes mellitus.
    Jenkins CR; Rittel A; Sturdivant RX; Wan J; Clerc PG; Manning E; Jenkins LM; Wardian JL; Graybill SD
    Andrology; 2021 Jul; 9(4):1076-1085. PubMed ID: 33606360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME).
    Rosen RC; Wu F; Behre HM; Porst H; Meuleman EJH; Maggi M; Romero-Otero J; Martinez-Salamanca JI; Jones TH; Debruyne FMJ; Kurth KH; Hackett GI; Quinton R; Stroberg P; Reisman Y; Pescatori ES; Morales A; Bassas L; Cruz N; Cunningham GR; Wheaton OA;
    J Sex Med; 2017 Sep; 14(9):1104-1115. PubMed ID: 28781213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing patient decisions to initiate and discontinue subcutaneous testosterone pellets (Testopel) for treatment of hypogonadism.
    Smith RP; Khanna A; Coward RM; Rajanahally S; Kovac JR; Gonzales MA; Lipshultz LI
    J Sex Med; 2013 Sep; 10(9):2326-33. PubMed ID: 23859250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
    Saad F; Caliber M; Doros G; Haider KS; Haider A
    Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
    [No Abstract]   [Full Text] [Related]  

  • 19. Associations of Renin-Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study.
    Campbell PJ; Axon DR; Taylor AM; Pickering M; Black H; Warholak T; Chinthammit C
    J Am Heart Assoc; 2020 Sep; 9(17):e016094. PubMed ID: 32844732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment patterns of testosterone replacement medications.
    Donatucci C; Cui Z; Fang Y; Muram D
    J Sex Med; 2014 Aug; 11(8):2092-9. PubMed ID: 24909541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.